ARTICLE | Clinical News
Amantadine: Completed Phase III enrollment
July 20, 2015 7:00 AM UTC
Adamas completed enrollment of about 120 patients in the double-blind, placebo-controlled, North American Phase III EASE LID trial evaluating 340 mg oral ADS-5102 once daily at bedtime for 26 weeks. ...